The Lantern Vol. 32, No. 3, Summer 1966

• Commandment Point • The Descendant • The Ultimate Journey • Thoughts While Riding New York Subway • Crazy Arthur • Confession • The Gull • One Boy • Cinquain: Cruel Life • Quality of Revenge • The Bull • Chinese Landscapehttps://digitalcommons.ursinus.edu/lantern/1089/thumbnail.jp

The Lantern Vol. 33, No. 1, Spring 1967

• The Implement • A Broken Backstop • City • My Friend Is • Meditation on Eight Dead Nurses and a Mad Austin Sniper • Fact and Fancy • Valhalla • A Blandishment • You Say You Were a Name So Sweet • Preview Rerun • To Lynne • Shards • The Initial Error • Daniel • Gold on Gold • If Morning Ever Comes • Third Poem to Tonya • The Kiss • Her Soul Was Slippery • Quietlyhttps://digitalcommons.ursinus.edu/lantern/1090/thumbnail.jp

The Lantern Vol. 33, No. 2, May 1967

• The Plea • Arrival • Nouvelle • Poem on Theme by Leroi Jones • Night Thoughts • Finals • Caught in the Act • Tomorrow • The Rail • The Price • Lost • It\u27s a Svaden Spring • No Thanks to City Hall • Grinding Them to Dust • Four • Five • Nine • Ten • Twelve • Thirty-Six • Psyched Up and Out • Gutted Gloryhttps://digitalcommons.ursinus.edu/lantern/1091/thumbnail.jp

The Lantern Vol. 32, No. 2, January 1966

• Mission 63 • The Kiss • The Dream • Silence is Golden • Self-Pity • The Excuse • Car Eighteen • Clothes Make the Man • The Place of a Just Man • Golden Gods • The Journey • Third Prize Picture • Gone Now • In Vain • Deep Dying • Marnie • Ruthttps://digitalcommons.ursinus.edu/lantern/1088/thumbnail.jp

The Lantern Vol. 34, No. 1, December 1967

• il se fait tard • il pleut • For GM • A Fragile Fragment • Epic in Stereo • Kisskraft • The Critical Marquis • Sea Flame • Belladonna • Haiku • Symphony • Ziegfortenblat • It\u27s One of Those Nights • Contentment • Short-sighted and Mildly Unbelievable • Society\u27s Children • Crowded Mirrors • Child in Bright Colors • The Long-range Accident • The Ultimate Machine • They Live in a Crowded Area • Beastiary • Nocturne • I am Like a Candle • Two A.M. and After • Question Times Ten • College Blues • Poem at Midnight • Love Chaos-Style • Once Knew a Homespun Nanny • He Who Argues • Dying by the Water • Is This Prose • The Subintellectual • Untitled Series • Sunset Skirmish • Lyrics of the Field • That Day When I See • Haiku • When the Shadows Stopped • Luz-Maria • Prayerhttps://digitalcommons.ursinus.edu/lantern/1092/thumbnail.jp

The Lantern Vol. 34, No. 2, May 1968

• The Man Without a System • A Medal for Malcolm • On Hearing That Tonya Will Be Married • The Black Sea • Odyssey \u2767 • Second Poem to Chris • Singularity • Period 5-A Began • Long and Aching Ride • Souvenirs • My Eschatological Epitaph • Discotheque • Some Borrowed Words • False Breakthrough • Shore Morning • The Beholder • Thursday Childless • A Most Prominent Role • It Ran Out • Shades of the Living • The Dark Night of the Mind II • One Step Beyond the Doors • A Note of Thanks to My Parents and Teachers • To a Dead Hippie • A Scrap • Love • Haiku No. 30 • Rachel • There Is No Present • Winter Woods • One Hundred Per Cent Genuine • Heaven • Silence Is Like God • I Soaked Up Silence • Opened Letter From Whistler Homer, Insaned Assailant • Sol Clutch Rides Tonight • I Have Seen Destruction • Upon That Night • That\u27s Weird • Alone • Kathy\u27s Tune • On Walking Home • The Wheel • Some Excuse, at Least • Freedom to Flap • Awareness • Okay, You Guys • You Say You Dream • Bacci Miahttps://digitalcommons.ursinus.edu/lantern/1093/thumbnail.jp

Tumor CD155 expression is associated with resistance to anti-PD1 immunotherapy in metastatic melanoma

Purpose: Resistance to anti-PD1 based immune checkpoint blockade (ICB) remains a problem for the treatment of metastatic melanoma. Tumor cells as well as host myeloid cells can express the immune checkpoint ligand CD155 to regulate immune cell function. However, the effect of tumor CD155 on the immune context of human melanoma has not been well described. This observational study characterizes tumor CD155 ligand expression by metastatic melanoma tumors and correlates results with differences in immune cell features and response to ICB. Experimental Design: Pre-treatment tumor specimens, from 155 metastatic melanoma patients treated with ICB and from 50 patients treated with BRAF/MEK-directed-targeted therapy, were assessed for CD155 expression by immunohistochemistry. Intratumor T cell features were analysed using multiplex-immunohistofluorescence for CD8, PD1 and SOX10. Correlations were made between CD155 tumor level and bulk tumor RNA-seq results, as well as clinical RECIST response and progression-free survival. Results: High pretreatment CD155 tumor levels correlated with high parenchymal PD1+CD8+/CD8+ T cell ratios (PD1tR) and poor response to anti-PD1 therapy. In PD-L1 negative tumors, high CD155 tumor expression was associated with patients who had poor response to combination anti-PD1/CTLA4 therapy. Conclusions: Our findings are the first to suggest that tumor CD155 supports an increase in the fraction of PD1+CD8+ T cells in anti-PD1 refractory melanoma tumors and, further, that targeting the CD155 pathway might improve response to anti-PD1 therapy for metastatic melanoma patients